Nurix Therapeutics Inc (NRIX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.69B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nurix Therapeutics Inc (NRIX) Stock Forecast
Analysts expect Nurix Therapeutics (NRIX) to earn $3.02 per share in the fiscal year ending Nov 30, 2026, on revenue of $744.85M. Of 14 analysts, 13 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Nov 30, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 1.71, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 35.7% |
| Buy | 8 | 57.1% |
| Hold | 1 | 7.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a profit to a loss and revenue estimates fall 83.5%.
- Fiscal year ending Nov 30, 2026
- $3.02
- EPS consensus, revenue $744.85M
- Fiscal year ending Nov 30, 2027
- -$1.28
- EPS consensus, revenue $123.22M
- Next report
- Jan 26, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Nov 30, 2026 | $3.02 | $2.96 to $3.10 | 3 | $744.85M | $704.05M to $785.20M | 4 |
| Nov 30, 2027 | -$1.28 | -$2.48 to -$0.62 | 3 | $123.22M | $58.00M to $200.00M | 4 |
Quarterly Estimates
The EPS consensus falls from -$0.50 for the quarter ending Nov 30, 2026 to -$0.59 for the quarter ending Feb 28, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Nov 30, 2026 | -$0.50 | -$0.79 to $0.04 | 16 | $36.08M | $4.90M to $101.64M | 15 |
| Feb 28, 2027 | -$0.59 | -$0.59 to -$0.59 | 1 | $15.00M | $15.00M to $15.00M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Nov 30, 2026 | 0 | 3 |
| Fiscal year ending Nov 30, 2027 | 0 | 1 |
| Quarter ending Feb 28, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Nov 30, 2026 has risen 68.7% from $1.79.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Nov 30, 2026 | $3.02 | $3.02 | $3.38 | $3.38 | $1.79 | +69.0% |
| Fiscal year ending Nov 30, 2027 | -$1.28 | -$1.28 | -$1.07 | -$1.07 | -$1.44 | N/A |
| Quarter ending Feb 28, 2027 | -$0.59 | -$0.59 | -$0.44 | -$0.44 | -$0.44 | N/A |
Frequently Asked Questions About NRIX
What is the NRIX stock forecast?
Consensus analyst estimates put Nurix Therapeutics's EPS at $3.02 for the fiscal year ending Nov 30, 2026, on revenue of $744.85M. The consensus rating from 14 analysts is Buy.
How do analysts rate NRIX stock?
Of 14 analysts covering Nurix Therapeutics, 5 rate it Strong Buy, 8 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NRIX next year?
For the fiscal year ending Nov 30, 2026, the consensus EPS estimate is $3.02, with estimates from $2.96 to $3.10 from 3 analysts. For the fiscal year ending Nov 30, 2027, the consensus EPS estimate is -$1.28, with estimates from -$2.48 to -$0.62 from 3 analysts.
What revenue do analysts expect from Nurix Therapeutics next year?
For the fiscal year ending Nov 30, 2026, the consensus revenue estimate is $744.85M, with estimates from $704.05M to $785.20M. For the fiscal year ending Nov 30, 2027, the consensus revenue estimate is $123.22M, with estimates from $58.00M to $200.00M.
How many analysts cover NRIX?
14 analysts rate Nurix Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Nov 30, 2026.
NRIX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors